These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1951 related articles for article (PubMed ID: 8509212)

  • 21. Two autologous melanoma-specific and MHC-restricted human T cell clones with identical intra-tumour reactivity do not share the same TCR V alpha and V beta gene families.
    Sensi M; Castelli C; Anichini A; Grossberger D; Mazzocchi A; Mortarini R; Parmiani G
    Melanoma Res; 1991; 1(4):261-71. PubMed ID: 1668534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T cell-receptor V gene use by CD4+ melanoma-reactive clonal and oligoclonal T-cell lines.
    Nishimura MI; Custer MC; Schwarz SL; Parker LL; Mixon A; Clay TM; Yannelli JR; Rosenberg SA
    J Immunother; 1998 Sep; 21(5):352-62. PubMed ID: 9789197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytotoxic activity and T cell receptor repertoire in tumor-infiltrating lymphocytes of adrenal cell carcinomas.
    Yamamoto Y; Backlin K; Nakagomi H; Halapi E; Juhlin C; Bucht A; Kiessling R
    Cancer Immunol Immunother; 1993 Aug; 37(3):163-8. PubMed ID: 8334679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of T-cell receptor V beta repertoire in ovarian tumour-reacting CD3+ CD8+ CD4- CTL lines.
    Fisk B; Flytzanis CN; Pollack MS; Wharton JT; Ioannides CG
    Scand J Immunol; 1994 Dec; 40(6):591-600. PubMed ID: 7848491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas.
    Halapi E; Yamamoto Y; Juhlin C; Jeddi-Tehrani M; Grunewald J; Andersson R; Hising C; Masucci G; Mellstedt H; Kiessling R
    Cancer Immunol Immunother; 1993; 36(3):191-7. PubMed ID: 8439980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An analysis of T-cell-receptor variable-region genes in tumor-infiltrating lymphocytes within malignant tumors.
    Nitta T; Sato K; Okumura K; Steinman L
    Int J Cancer; 1991 Oct; 49(4):545-50. PubMed ID: 1655662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional and molecular characterization of tumour-infiltrating lymphocytes and clones thereof from a major-histocompatibility-complex-negative human tumour: neuroblastoma.
    Facchetti P; Prigione I; Ghiotto F; Tasso P; Garaventa A; Pistoia V
    Cancer Immunol Immunother; 1996 Mar; 42(3):170-8. PubMed ID: 8640845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T-cell receptor V beta gene usage of human cytotoxic T-cell clones obtained from gastric cancer patients.
    Miyahara E; Yamaguchi Y; Minami K; Hihara J; Noma K; Toge T; Takafuta T; Fujimura K
    Anticancer Res; 1999; 19(3A):2057-66. PubMed ID: 10470148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of fresh (uncultured) tumour-infiltrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma.
    Mitropoulos D; Kooi S; Rodriguez-Villanueva J; Platsoucas CD
    Clin Exp Immunol; 1994 Aug; 97(2):321-7. PubMed ID: 8050183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of a T-cell receptor from a therapeutic murine T-cell clone.
    Shilyansky J; Yang JC; Custer MC; Spiess P; Mixon A; Cole DJ; Mulé JJ; Rosenberg SA; Nishimura MI
    J Immunother; 1997 Jul; 20(4):247-55. PubMed ID: 9220314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor-infiltrating CD3- NK cells are more effective than CD3+ T cells in killing autologous melanoma cells.
    Azogui O; Avril MF; Margulis A; Guillard M; Caillou B; Prade M
    J Invest Dermatol; 1991 Sep; 97(3):425-9. PubMed ID: 1831465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of T-cell-receptor beta-chain-gene usage in peripheral-blood and tumor-infiltrating lymphocytes from human non-small-cell lung carcinomas.
    Echchakir H; Asselin-Paturel C; Dorothee G; Vergnon I; Grunenwald D; Chouaib S; Mami-Chouaib F
    Int J Cancer; 1999 Apr; 81(2):205-13. PubMed ID: 10188720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes.
    Lüscher U; Filgueira L; Juretic A; Zuber M; Lüscher NJ; Heberer M; Spagnoli GC
    Int J Cancer; 1994 May; 57(4):612-9. PubMed ID: 8181865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of restricted T-cell receptor beta-chain variable region (V beta) usage of reactive T-lymphocytes in Hodgkin's disease.
    Meggetto F; al Saati T; Rubin B; Delsol G
    Br J Haematol; 1994 Mar; 86(3):524-32. PubMed ID: 8043434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential effects of interleukin-2 and CD3 triggering on cytokine gene transcription and secretion in cultured tumor infiltrating lymphocytes.
    Filgueira L; Zuber M; Juretic A; Lüscher U; Caetano V; Harder F; Garotta G; Heberer M; Spagnoli GC
    Cell Immunol; 1993 Aug; 150(1):205-18. PubMed ID: 8343966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The emergence of non-cytolytic NK1.1+ T cells in the long-term culture of murine tumour-infiltrating lymphocytes: a possible role of transforming growth factor-beta.
    Tamada K; Harada M; Ito O; Takenoyama M; Mori T; Matsuzaki G; Nomoto K
    Immunology; 1996 Dec; 89(4):627-35. PubMed ID: 9014832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.
    Itoh K; Platsoucas CD; Balch CM
    J Exp Med; 1988 Oct; 168(4):1419-41. PubMed ID: 3262710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
    Hayakawa K; Salmeron MA; Parkinson DR; Markowitz AB; von Eschenbach AC; Legha SS; Balch CM; Ross MI; Augustus LB; Itoh K
    J Immunother (1991); 1991 Oct; 10(5):313-25. PubMed ID: 1790139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
    Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
    PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide.
    Salgaller ML; Weber JS; Koenig S; Yannelli JR; Rosenberg SA
    Cancer Immunol Immunother; 1994 Aug; 39(2):105-16. PubMed ID: 7519125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 98.